Ranbaxy Laboratories: $500M FDA/DOJ Settlement

What happened

The US FDA conducted inspections of Ranbaxy Laboratories' pharmaceutical manufacturing facilities in India and found systematic failures in the documentation of manufacturing processes. The issues included incomplete batch records, inaccurate cleaning records, and inadequate investigations of manufacturing failures. The core finding was not that Ranbaxy's drugs were necessarily unsafe, but that the documentary evidence needed to verify whether manufacturing had been conducted to Good Manufacturing Practice standards was missing or inconsistent. Without that contemporaneous documentation, the FDA could not verify compliance. Ranbaxy agreed to a $500 million settlement and faced import alerts that banned affected products from the US market. GMP documentation, including batch records, cleaning records, test records, and failure investigations, is exactly the type of contemporaneous evidence that blockchain timestamping is designed for. A timestamp at the moment of each record's creation creates an unbroken chain of evidence that no inspection can challenge on timeliness grounds.